The National Institute on Drug Abuse (NIDA) intends to modify an existing sole-source contract to increase its maximum value by $3,718,289, raising the total to $17,722,619, to continue the synthesis and distribution of drugs of abuse and related compounds for research. The contract supports the production, analysis, and distribution of controlled and research chemicals, including labeled and unlabeled compounds, for preclinical and clinical trials addressing substance use. The ordering period runs from June 9, 2022, to June 8, 2027, with no changes to this timeline. Performance of services is not specified beyond the contract’s scope, which includes maintaining the NIDA drug supply inventory and database. No budget details beyond the stated increase are provided.